MDGEF (Medigene AG) Net Income From Continuing Operations : $-16.94 Mil (TTM As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Medigene AG Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Medigene AG's net income from continuing operations for the six months ended in Jun. 2024 was $-7.24 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2024 was $-16.94 Mil.

Medigene AG Net Income From Continuing Operations Historical Data

The historical data trend for Medigene AG's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Net Income From Continuing Operations Chart

Medigene AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-22.13

-34.55

-11.62

-9.93

-18.09

Medigene AG Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Net Income From Continuing Operations	Get a 7-Day Free Trial															15.30	-25.26	-8.34	-9.70	-7.24

Medigene AG Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-16.94 Mil.

Medigene AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (OTCPK:MDGEF) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

MDG2:Austria

Address

Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.